NCT00152997 - Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

December 31, 2005

Conditions

Restless Legs Syndrome

Interventions

DRUG

Pramipexole 0.125 mg tablets

DRUG

Pramipexole 0.125 mg tablets Placebo

Trial Locations (7)

Boehringer Ingelheim Investigational Site, Akita, Akita

Boehringer Ingelheim Investigational Site, Kochi, Kochi

Boehringer Ingelheim Investigational Site, Kurume, Fukuoka

Boehringer Ingelheim Investigational Site, Otaru,Hokkaido

Boehringer Ingelheim Investigational Site, Sakai, Osaka

Boehringer Ingelheim Investigational Site, Shibuya,Tokyo

Boehringer Ingelheim Investigational Site, Takatsuki, Osaka